FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
2019 · Clinical Cancer Research · 152 citations
https://doi.org/10.1158/1078-0432.ccr-19-2580
L
Lola A. Fashoyin‐Aje
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
124
Papers
3.4K
Citations
28
h-index
43
i10-index
Lola A. Fashoyin‐Aje is an academic researcher from Center for Biologics Evaluation and Research. The author has contributed to research in topics: Economic and Financial Impacts of Cancer & Health Systems, Economic Evaluations, Quality of Life & Ethics in Clinical Research. The author has an h-index of 28, co-authored 106 publications.
ORCID: 0000-0001-7328-7813Papers by this author
worksFDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
2020 · Clinical Cancer Research · 87 citations
https://doi.org/10.1158/1078-0432.ccr-19-3980
Operational strategies in US cancer centers of excellence that support the successful accrual of racial and ethnic minorities in clinical trials
2020 · Contemporary Clinical Trials Communications · 36 citations
https://doi.org/10.1016/j.conctc.2020.100532
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, <i>HER2</i> -Positive <i>RAS</i> Wild-Type Colorectal Cancer
2023 · Clinical Cancer Research · 35 citations
https://doi.org/10.1158/1078-0432.ccr-23-1041
FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette–Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer
2024 · Clinical Cancer Research · 21 citations
https://doi.org/10.1158/1078-0432.ccr-24-2812
To Adjudicate or Not Adjudicate
2022 · JACC CardioOncology · 0 citations
https://doi.org/10.1016/j.jaccao.2022.11.003
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat